NICO Corporation is set to introduce its latest product, the NICO Myriad SPECTRA System, at the upcoming American Association of Neurosurgical Surgeons (AANS) Annual Scientific Meeting in Chicago, Booth #825. 

This technology promises enhanced visualization and precision in tumor and clot removal, marking a notable advancement in neurosurgical capabilities.

The NICO Myriad SPECTRA System represents a leap forward in neurosurgical technology. Its hand-held design, coupled with the provision of white and blue light sources, offers neurosurgeons unprecedented control and clarity during surgical procedures.

Designed to address the challenges of brain tumor removal and intracerebral hemorrhages (ICH), the SPECTRA System combines illumination, resection, collection, and tissue preservation functionalities. By seamlessly integrating with both minimally invasive and open craniotomy approaches, it promises to revolutionize neurosurgical techniques.

"The versatility of the Myriad SPECTRA System is unparalleled," commented Dr. Costas Hadjipanayis, Director of the Center for Image-Guided Neurosurgery at the University of Pittsburgh Medical Center (UPMC). "Its ability to toggle between white and blue light facilitates fluorescence-guided surgery, ensuring maximal safe removal of high-grade glioma tumor tissue," said Dr. Hadjipanayis.

Fluorescence-guided surgery has emerged as a crucial tool in neurosurgery, aiding surgeons in achieving precise tumor resections. The SPECTRA System's capability to deliver excitation light close to the surgical field enhances tissue fluorescence, enabling more accurate and thorough procedures.

In addition to its advanced light delivery features, the SPECTRA System prioritizes surgeon comfort and workflow efficiency. "We recognize the importance of optimizing surgical workflows and clinical efficiencies," stated Jim Pearson, President and CEO of NICO Corporation. "The Myriad SPECTRA System is a testament to our commitment to providing neurosurgeons with cutting-edge technologies that elevate patient care while streamlining operating room processes," added Pearson.

The recent FDA clearance and registration with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom further validate the safety and efficacy of the SPECTRA System, paving the way for its adoption in neurosurgical practices worldwide.